Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
2020-000185-42Phase 2Unknown
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inaxaplin in focal segmental glomerulosclerosis (FSGS), sponsored by Vertex Pharmaceuticals. Primary endpoint: Percent change from baseline in urine protein to creatinine ratio (UPCR) at Week 13. Status: unknown.
02
Drugs
inaxaplin
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on 2020-000185-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000185-42.